PDF
ZENODO
Published
2025-09-30
Section
Articles
How to Cite
How to Cite
SUYAK SARKOMALARI NUR TASHXISI: OSTEOSARKOMANING RADIOLOGIK BAHOLANISHI
Aktamova Zarnigor
Toshkent davlat tibbiyot universiteti, magistr
Keywords: osteosarkoma, suyak sarkomalari, rentgenografiya, KT, MRT
Abstract
Osteosarkoma suyakning eng keng tarqalgan birlamchi malign o‘smasi bo‘lib, ko‘pincha distal femur va proksimal tibia metafiz sohalarida uchraydi. Mazkur maqolada osteosarkomaning diagnostikasida qo‘llaniladigan asosiy nur tashxis usullari – rentgenografiya, kompyuter tomografiyasi (KT), magnit-rezonans tomografiya (MRT), positron-emission tomografiya (PET/KT) va suyak sintigrafiyasi keng yoritilgan. Xususan, turli xalqaro tashkilotlarning (NCCN, ESMO, SELNET) klinik ko‘rsatmalari solishtirib tahlil qilingan. Shuningdek, davolashdan keyingi kuzatuv taktikasi, nur tashxisining imkoniyatlari va cheklovlari muhokama etilgan
References
1. Bacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P. (2006). Prognostic factors in nonmetastatic osteosarcoma of the extremities: Experience at the Rizzoli Institute. Cancer, 106(5), 1154–1161. https://doi.org/10.1002/cncr.21725
2. Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., ... & Winkler, K. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 20(3), 776–790. https://doi.org/10.1200/JCO.2002.20.3.776
3. Kager, L., Zoubek, A., Potschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., ... & Bielack, S. (2003). Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group (COSS) protocols. Journal of Clinical Oncology, 21(10), 2011–2018. https://doi.org/10.1200/JCO.2003.08.132
4. Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist, 9(4), 422–441. https://doi.org/10.1634/theoncologist.9-4-422
5. Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., ... & Goorin, A. M. (2005). Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology, 23(9), 2004–2011. https://doi.org/10.1200/JCO.2005.05.054
6. National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2023. Retrieved from https://www.nccn.org
7. European Society for Medical Oncology (ESMO). (2021). Osteosarcoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(9), 1189–1201. https://doi.org/10.1016/j.annonc.2021.06.007
8. Piperno-Neumann, S., Le Deley, M. C., Rédini, F., Pacquement, H., Marec-Bérard, P., Petit, P., ... & Oberlin, O. (2016). Sarcoma European-Latin American Network (SELNET) guidelines for osteosarcoma management. Cancer Treatment Reviews, 49, 43–50. https://doi.org/10.1016/j.ctrv.2016.07.005
9. Ottaviani, G., & Jaffe, N. (2009). The epidemiology of osteosarcoma. Cancer Treatment and Research, 152, 3–13. https://doi.org/10.1007/978-1-4419-0284-9_1
10. Whelan, J. S., & Davis, L. E. (2018). Osteosarcoma, chondrosarcoma, and chordoma. Journal of Clinical Oncology, 36(2), 188–193. https://doi.org/10.1200/JCO.2017.75.1743
